NEW YORK ( TheStreet) -- BioMimetic Therapeutics (Nasdaq: BMTI) hit a new 52-week low Wednesday as it is currently trading at $6.17, below its previous 52-week high of $14.80 with 124,261 shares traded as of 11:45 a.m. ET. Average volume has been 537,400 shares over the past 30 days.

BioMimetic has a market cap of $185.8 million and is part of the health care sector and health services industry. Shares are down 50.2% year to date as of the close of trading on Tuesday.

BioMimetic Therapeutics, Inc., a biotechnology company, engages in the development and commercialization of regenerative protein therapeutic-device combination products for the treatment of musculoskeletal injuries and conditions affecting bones, tendons, ligaments, and cartilage.
  • Practice your BMTI trading strategies and win cash in our stock game.

TheStreet Ratings rates BioMimetic as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. You can view the full BioMimetic Ratings Report.

See all 52-week low stocks or get investment ideas from our investment research center.